ILMNIllumina, Inc.
Is the price fair?
A demanding price: priced for +16% a year vs +0% a year delivered and rich vs its sector.
Priced for ~16% a year FCF growth. The price already bakes in strong, sustained growth.
In its normal range: P/E 50.3 vs a 52.2 median over 29 quarters (−4% vs median).
Sector median 25.1× across 135 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
Unless marked, from derived, as of Jun 28, 2026.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What ILMN's price assumes
Illumina, Inc. trades at 50.3× earnings against 36.7× for the median Diagnostics & Research name, more expensive than its own group.
Trailing P/E · Diagnostics & Research median 36.7 · 1.37× the median: the market pays up for this one
- Price / sales
- 9.05
Price / sales · today's price, trailing year to Jun 28, 2026
- Free cash flow yield
- 2.3%
Free cash flow yield · Diagnostics & Research median 2.9%
- Growth the price implies
- +16%
Growth the price implies · The price pays for +16% free cash flow growth a year for a decade; revenue has held flat over the last three.
Details›
- Price / booktoday's price, trailing year to Jun 28, 2026
- 14.3
- EV / EBITtoday's price, trailing year to Jun 28, 2026
- 47.0
- EV / salestoday's price, trailing year to Jun 28, 2026
- 9.24
- Healthcare median P/E503 names
- 27.9
- Diagnostics & Research median P/E33 names
- 36.7
- Free cash flow, trailing twelve months
- $931M
- Market capitalisation151.0 million shares, counted Jul 24, 2026
- $40.7B
- 3-year revenue growth
- +0.24%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $195.97 |
| Its own P/E history, median | $279.67 |
| Its own P/E history, upper quartile | $362.79 |
| 52-week range | $95.03 – $293.84 |
| Today | $269.37 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
What is it worth?
Today's price against what its own multiples, its cash flow and your growth assumption say it is worth.
Against its own past
Its multiples now against their own history, and how much of the price move came from earnings rather than the multiple.
Diagnostics & Research
Ranks #8 of 21 by RyuScore